Bavarian Biotech Mission to Japan October 2012

Transcription

1 Bavarian Biotech Mission to Japan October 2012

2 Bavarian Biotech Mission to Japan October 2012 Germany Bavaria Munich Bavarian Biotech Cluster: 300 biotech & pharma companies 5 biotech incubators 35 universities, 3 with elite or excellence status t 5 university clinics 3 Max Planck Institutes (Life Sc.) Helmholtz Zentrum München 8 Fraunhofer institutes 6 national health research centers

3 Munich Biotech Cluster m 4 The innovative, research-driven life science and biotech industry in Bavaria (Southern Germany) is growing consistently, striving not only to keep its status as a leading bioregion in Europe but also to put Bavaria on the global map. The regional R&D companies are focused on drug development in the field of personalized medicine and possess a promising and well-filled drug discovery pipeline. The Bavarian Biotechnology Cluster is supported by innovative companies providing cutting-edge services and a strong regional representation of internationally acting Clinical Research Organizations. In 2010, the Munich Biotech Cluster was awarded "Germany s Leading-Edge Cluster - status by the federal government, bringing the potent initiative m 4 - Personalized Medicine and Targeted Therapies to the region. This initiative is now highly active, with 40 R&D projects, and has already led to the first success stories ( The Bavarian Biotechnology Cluster is coming to Japan in October 2012, with a delegation of 16 companies - offering innovative biotech R&D technologies as well as products and services for the life science industry. The delegation members are available for partnering meetings with Japanese companies in Osaka on October 9 and in Yokohama on October at the Bavarian booth at Bio Japan World Business Forum Bio M is the organizer of the Japan mission and coordinator of the Bavarian Biotechnology Cluster and the Munich Biotech Cluster, supporting more than 300 companies and offering a gateway to the Bavarian biotech industry for partners worldwide. Bio M s website ( provides an overview on the different activities and actors within the region, including the m 4 initiative, up-to-date news, a company database, a job forum and much more. Our partner Bayern International ( is a service unit of the Bavarian government and supports the mission by providing a Bavarian booth at Bio Japan. Bio M Biotech Cluster Development GmbH Address: Am Klopferspitz 19 a, Martinsried, Germany Tel.: +49 (0) Fax: +49 (0) Contact: Prof. Dr. Horst Domdey, CEO domdey@bio-m.de Website:

4 BAYERN INTERNATIONAL Bayern International is an export-promotion company of the Free State of Bavaria for small and medium-sized Bavarian companies and also responsible for the marketing of Bavaria as a business location. Bayern International was founded in 1996 by the state of Bavaria within the framework of the Bavarian Future Initiative ( Offensive Zukunft Bayern ). It was Germany s first economic promotion corporation to be certified pursuant to DIN ISO Our staff have long-term experience in the organization and implementation of export promotion measures and location marketing. We work in close cooperation with partners from the government and economic institutions, both in Bavaria and worldwide. Our project group Invest in Bavaria promotes Bavaria as an attractive business location. BAYERN INTERNATIONAL - Bayerische Gesellschaft für Internationale Wirtschaftsbeziehungen mbh Address: Landsberger Str. 300, Munich, Germany Tel.: +49 (0) Fax: +49 (0) Contact: Torsten Wagner, Project Manager twagner@bayern-international.de Website:

5 4SC Discovery 4SC Discovery GmbH is a wholly-owned subsidiary of 4SC AG that offers technologies and tailored research services covering drug discovery and chemical optimization through to a preclinical development candidate. The company offers customers in the pharmaceutical, biotech and chemical industries the cost and timeto-market benefits that result from a drug discovery and optimization process aided by 4SC s proprietary in-silico screening technology, which has been successfully employed in multiple research collaborations in past and present. Through the integrated drug discovery platform i2c (idea to candidate) 4SC Discovery is able to offer a seamless process from early concept through to a preclinical development candidate. i2c is a strategic collaboration of 4SC Discovery that complements the company s own capacities and expertise in computational, medicinal and analytical chemistry, biology and pharmacology in an ideal way with Crelux GmbH s capabilities in protein production, crystallography and INTRACT screening. The i2c client groups are pharmaceutical companies looking to outsource part of their early discovery projects and also small and mid-size biotech companies seeking to complement their own infrastructure. Besides the standard fee-for-service offerings, i2c also includes research collaborations based on risk sharing models including milestones and royalties. Collaborations are provided as tailor made solutions for smaller sized companies and interested pharmaceutical partners. In addition, 4SC Discovery also applies its comprehensive pharmacological expertise to investigating new compounds in the areas of cancer and autoimmune disease. 4SC Discovery aims to engage in partnerships with pharmaceutical and biotech companies to accelerate the development of its research programs and further advance their commercialization. 4SC Discovery GmbH Address: Am Klopferspitz 19 a, Martinsried, Germany Tel.: +49 (0) Fax: +49 (0) Contact: Dr. Andrea Aschenbrenner, Head of Customer Relations and Business Development andrea.aschenbrenner@4sc.com Website:

6 Ascenion Ascenion GmbH is an independent IP asset management company focused on life sciences. Ascenion advises and supports public research institutions with regard to the protection and exploitation of their intellectual property (patents, knowledge, materials), and initiates and mediates license agreements between research institutions and industry. With Ascenion s support commercially attractive inventions, materials and know-how are promptly identified and given appropriate patent protection. Ascenion finds suitable industrial partners, negotiates licensing and cooperation agreements, and accompanies start-ups on the road to independence. Ideas thereby lead to new jobs and products, such as a novel anti-cancer drug or a procedure for identifying harmful bacteria in drinking water. The proceeds from commercialization flow back to the research institutions. Ascenion is the exclusive partner of 24 life-science institutes in the Helmholtz and Leibniz Associations and of one Medical School, and coordinates technology transfer for the German National Genome Research Network. Ascenion currently markets around 750 technologies on behalf of these institutes and closes an average of about 70 agreements between research and industry per year. The team has also coached numerous spin-offs through their foundation and early growth, and Ascenion holds equity in 25 of these companies. Ascenion s headquarters are in Munich, Germany, with further offices in Berlin, Braunschweig, Hamburg, Hanover and Neuherberg. Ascenion GmbH Address: Herzogstr. 64, Munich, Germany Tel.: +49 (0) Fax: +49 (0) Contact: Dr. Christian Stein, CEO stein@ascenion.de Website:

7 Aurigon Life Science AURIGON Life Science is an independent, d privately-owned, German contract t research institute dedicated to non-clinical services for human and veterinary pharmaceuticals, food and chemicals. AURIGON provides a full range of experimental and advisory services. From early phase product efficacy and safety evaluation to regulatory toxicology and late stage pre-marketing testing, we cover all areas of non-clinical development. We have extensive experience in working with a broad variety of molecules. We also specialize in biologics such as peptides and proteins, antibodies, biosimilars, RNA and DNA, vaccines and cell therapy. AURIGON s studies meet international standards and can be performed in compliance with GLP or GMP regulations. Our transparent Quality Management System, together with our continuous pursuit of innovation, guarantees compliance with ever changing global regulatory requirements. Services of AURIGON include: ADME/PK - pharmacology efficacy testing, safety - pharmacology - biological activity testing, bioassays, batch release - analytics - toxicity testing (genotoxicity, general toxicology, immunotoxicity, reprotoxicity, carcinogenicity) - consultancy - archiving AURIGON carefully evaluates your project, from both the scientific and regulatory aspects, and strives to follow the most appropriate strategy to achieve your milestones in a time- and cost-effective manner. Wherever your innovative therapy target of tomorrow comes from we support you in characterization and establishing effective proof of concept studies. We also support you in the safety assessment for translation into the clinics. We are a trusted outsourcing partner for multinational pharmaceutical and chemical groups, food producers and dynamic biotechnology companies. Rely on German Principals: Ihr Ziel ist unsere Aufgabe! Aurigon Life Science GmbH Address: Bahnhofstr. 9-15, Tutzing, Germany Tel.: +49 (0) Fax: +49 (0) Contact: Dr. Stefan Krawielitzki, Manager Business Development E Mail: info@aurigon de info@aurigon.de Website:

8 Cfm Oskar Tropitzsch Established in 1788 as 1 st chemical factory in Germany Cfm Oskar Tropitzsch e.k. assists the chemical, pharmaceutical and biotechnological industry in sourcing and producing chemical specialties. The core of our work is to supply the product which our customer is looking for - with the right documentation (customized DMF), the correct quantity from lab scale to production scale and proper quality. As reliable partner of well-known companies Cfm Oskar Tropitzsch focus to establish a long-term relation to its customers and suppliers to support projects from RnD state up to commercial production. To achieve these challenging goals Cfm Oskar Tropitzsch uses its excellent knowhow and worldwide network of qualified suppliers. Finding the best solution!...it's not just a sentence it s our mission! Cfm Oskar Tropitzsch is specialized in the following core markets: Biochemicals made by fermentation Mycotoxins Antibiotics Substances for Apoptose (i.e. Geldanamycin, K-252a, Rapamycin, LL-Z ) Phytochemicals Plant extraction, Plant extracts, standard reference materials > 800 Medicinal Plants/Herbs (roots, barks, seeds, leaves: dried or fresh) Extracts as pharmaceutical raw materials (incl. required documents) Natural Toxins; either from animals directly or natural toxins produced by Peptide Synthesis (snakes, bees, spiders, scorpions, amphibians). Contract manufacturing of APIs Excipients Chemical Specialties Small-scale production (non-gmp, GMP, including DMF/ASMF establishment) Cfm Oskar Tropitzsch would be pleased to get in contact with your valuable company and to start a long term relation. We are looking for customers, but also for suppliers and CMOs/CROs. Cfm Oksar Tropitzsch e.k. Address: Waldershofer Str , Marktredwitz, Germany Tel: +49 (0) Fax: +49 (0) Contact: Oskar Tropitzsch, CEO E Mail: oskar tropitzsch@cfmot de oskar.tropitzsch@cfmot.de Website:

9 Coriolis Pharma Science-driven Formulation and Lyophilization Development Services for Biopharmaceuticals Coriolis Pharma is a globally operating independent service provider for research and development of formulations and lyophilization processes of (bio)pharmaceutical drugs (proteins, peptides, monoclonal antibodies, RNA/DNA etc.) and vaccines. An interdisciplinary team of highly qualified scientists with many years of experience in the development of (bio)pharmaceuticals supported by an expert scientific advisory board provides cutting-edge service and know-how related to the formulation development of biopharmaceuticals. This may involve for example formulation development of (pre-)clinical material through to commercial products, lyophilization processes, stability testing, supply of pre-clinical material, and innovative analytical l technologies for aggregate analysis and particle characterization also for trouble shooting (e.g. Dynamic light scattering, Nanoparticle tracking, Coulter Counter, Archimedes, Analytical ultracentrifugation (AUC)). Coriolis Pharma has been successfully inspected to perform GMP compliant analysis using Light Obscuration, Micro-Flow Imaging (MFI), Asymmetric Flow Field Flow Fractionation (AF4) and Hollow Fiber Flow Field Flow Fractionation (HF5) and has now received a Certificate of GMP compliance from the competent regulatory agency. The unique combination of available methods, leading scientific expertise in the fields of biopharmaceutical formulation development and testing and the ability to offer those services in compliance with highest quality standards makes Coriolis Pharma an ideal partner for companies wishing to outsource particle and aggregation characterization of their biopharmaceutical. Coriolis Pharma Research GmbH Biopharmaceutical Research and Development Service Address: Am Klopferspitz 19, Martinsried, Germany Tel: +49 (0) Fax: +49 (0) Contact: Dr. Michael Wiggenhorn, CEO E Mail: contact@coriolis pharma com contact@coriolis-pharma.com Website:

10 ELLA Biotech ELLA Biotech, an independent and privately owned company founded in October 2004, is focused on the production of high quality and special oligonucleotides following quality standards which you would appreciate and expect in your own lab. We offer an extremely reliable service for the custom synthesis of oligonucleotides according to the needs and ideas of our customers. The ELLA-Team shares several decades of experience in oligonucleotide synthesis and combines an interdisciplinary mix of skills essential for a smooth running synthesis lab: Nucleic acid chemists, biologists, technicians for equipment maintenance and lab managers experienced in oligonucleotide production according to DIN EN ISO 9001:2008 regulations. Our product portfolio includes primers and probes for diagnostics in compliance with ISO 13485:2003 and ISO 9001:2008 standards, highquality long oligonucleotides (e.g. aptamers) and also randomized oligonucleotides using trinucleotides (Trimers). ELLA Biotech GmbH Address: Am Klopferspitz 19, Martinsried, Germany Tel: +49 (0) Fax: +49 (0) Contact: Iris Heigl, Marketing & Sales irisheigl@ellabiotech.com Website:

11 FGK Clinical Research FGK Clinical Research GmbH is a Europe-based full service Contract Research Organization offering the complete range of clinical development and consulting services to pharmaceutical, biotechnology and medical device companies. Employing more than 80 highly-skilled and experienced professionals, FGK operates from Munich on local and global projects, covering clinical studies in Phases I to IV. FGK has extensive experience in all major therapeutic areas and clinical research fields allowing it to effectively design, manage and analyze development programs and clinical trials. FGK has subsidiaries in Prague, Warsaw, Budapest and London. We offer full service for the conduct of clinical trials including clinical trial management and clinical monitoring, regulatory submissions, biostatistics, data management, medical writing, quality assurance, pharmacovigilance and consulting services. FGK Clinical Research GmbH Address: Heimeranstr. 36, Munich, Germany Tel.: +49 (0) Fax: +49 (0) Contact: Dr. Edgar J. Fenzl, CEO edgar.fenzl@fgk-cro.com Website: com

12 FGK Representative Service FGK Representative Service GmbH was founded in order to meet the legal requirements of sponsor companies which do not have a subsidiary within the European Union for the purpose of performing clinical research projects in the European Union. Such legal representative for clinical drug trials or authorized representative for medical device trials fulfils the obligation that the sponsor companies must be established or represented in the European Union according to the Clinical Trials Directive 2001/20/EC. FGK represents its partners in all member states of the EU for drug and medical device trials to enable submissions of regulatory applications to the European authorities and ethics committees. FGK also represents overseas companies for all applications in drug authorizations and orphan drug designations. FGK also provides the service of "local representation" for Switzerland via their subsidiary in Zug, Switzerland. FGK Representative ti Service GmbH Address: Heimeranstr. 36, Munich, Germany Tel.: +49 (0) Fax: +49 (0) Contact: Dr. Edgar J. Fenzl, CEO edgar.fenzl@fgk-rs.com Website:

13 HYGLOS Hyglos GmbH is a biotech company located in Biotechnologie Zentrum Bernried (BZB), Munich area, Germany. Applying our proprietary technology we develop and produce highly specific phage derived recombinant proteins for detection of bacteria and anti-microbial applications. The resulting products are used in food safety testing, removal of microbial contaminations, human diagnostics as well as research applications. In the field of endotoxin detection Hyglos has introduced a ground-breaking new technology called EndoLISA. Endotoxins are specifically bound to the microtiter plate and interfering substances are completely removed by a wash procedure. The endotoxin content is quantified by means of recombinant Factor C and a fluorescent substrate. EndoLISA overcomes limitations of the currently used methods, such as LAL test. The advantages of this assay include the very broad measurement range, the ph tolerance range and the exceptional tolerance regarding buffer components such as salts, organic solvents, detergents and protease inhibitors. The new test offers reliable results and complete test solutions including all components needed for endotoxin detection. Concerning endotoxin removal we provide outstanding technology to our customers from biopharmaceutical research and industry. Based on endotoxin-specific recombinant phage proteins applied for affinity chromatography, EndoTrap reliably removes endotoxins from aqueous solutions of e.g. proteins, antibodies, vaccines, nucleic acids, buffers and various other substances with excellent sample recovery rates for maximized research and downstream results. The EndoTrap technology is currently the most powerful and convenient solution for endotoxin removal available and can easily be scaled up for lab research and industrial applications. For industrial application a regulatory support file is available. The Hyglos food microbiology product portfolio focuses on innovative bacteria capture systems targeting foodborne pathogens such as Listeria and EHEC. Magnetic particles coated with phage derived binding molecules are used to enrich bacteria from complex matrices. The technology offers outstanding bacterial capture performance and improves quality of microbiological testing as well as reduced time to result. Hyglos GmbH is certified according to ISO 9001:2008 and ISO 13485: AC:2007. HYGLOS GmbH Address: Am Neuland 3, Bernried, Germany Tel.: +49 (0) Fax: +49 (0) Contact: Dr. Wolfgang Mutter, General Manager wolfgang.mutter@hyglos.de g yg Website:

14 Intana Bioscience Intana Bioscience GmbH, based in Martinsried near Munich, is a privately owned service provider company, founded in Sept 2008 with currently 8 employees. Intana Bioscience GmbH offers interaction analysis based on a single molecule sensitive spectroscopic approach called Fluorescence Cross Correlation Spectroscopy (FCCS). By analyzing the diffusional behavior of molecules in solution, FCCS allows to determine the concentration of the interacting molecules, their size and their binding state and to calculate precisely the dissociation- and rate constants. The approach can be used to profile and investigate compounds, peptides, proteins, nucleic acids, antibodies and any target-ligand interaction label free and in high throughput. Supply with sufficient amounts of purified and active target protein has shown to be one of the pitfalls in classical assay development. Additionally purified proteins do not represent the physiological situation of a cell in which a future drug is supposed to unfold its effect. In contrast, FCCS can be applied in cellular lysates and living cells to determine affinity and kinetics of biomolecular interactions and bridges the gap between cellular and biochemical assays. It therefore represents a highly efficient approach to support the development of selective inhibitors for targeted therapies. Customers benefit from short assay development time, in depth interaction analysis and assay conditions that mimic the natural environment of a drug. Intana Bioscience GmbH Address: Lochhamer Str. 29 a, Martinsried, Germany Tel.: +49 (0) Fax: +49 (0) Contact: Dr. Stefan Hannus, Director & CSO stefan.hannus@intana.de Website:

15 INTERLAB INTERLAB looks forward to meeting Biotech and Pharmaceutical companies planning and per- forming clinical trials in Phases II or III. As a centralized laboratory INTERLAB is experienced in supporting these research companies directly or via contract research organizations (i.e. CROs). INTERLAB is an independent CENTRAL LABORATORY supporting regional, international and global clinical trials for pharmaceutical and biotechnology companies. INTERLAB has developed into a worldwide network of central laboratories dedicated to clinical research covering Europe, North and South America, Australia, Africa and Asia including India and China. The international head office is located in Munich, Germany. INTERLAB provides full-service analytical and logistical support as well as a wide range of routine and esoteric testing methods at highest quality standards Professional project managers (with PhD degree) coordinate all activities worldwide Study-specific instruction manuals and customized requisition forms Visit-specific kits to ease sample handling at sites, incl. monitoring of expiry dates & kit re-supply Cost-effective shipment logistics worldwide: ambient, refrigerated, frozen conditions Flexible data management and transfer All lab data collected worldwide in one single global database Same layout for all laboratory reports worldwide Storage capabilities: -20 C, -70 C, -80 C, liquid nitrogen Analytical methods in all therapeutic areas are available: clinical chemistry and hematology endocrinology and genetics, PCR microbiology and virology immunology and serology histopathologyand cytology toxicology and drug assays, incl. LC-MS/MS More than 1,500 different methods are available. In Europe, over 15,000 samples are processed daily by a staff of over 300; over 50,000 samples per day and over 6,000 staff worldwide a strong global laboratory network Standard operating procedures (SOPs) reflect the requirements of GCP and EN/EC/ISO15189, EN 45,001 and ISO 9002 Periodic cross-validation and internal audits of all partner laboratories Same global SOPs for study setup and data communication INTERLAB central lab services - worldwide GmbH Address: Bayerstraße 53, Munich, Germany Tel.: +49 (0) Fax: +49 (0) Contact: Dr. Hermann Schulz, CEO info@interlab.de Website:

16 IRIS Biotech IRIS Biotech is specialized in reagents for Drug Discovery, Drug Delivery, Diagnostics and Biocatalysis. We have specific know-how and production capabilities to manufacture and supply products from the following areas from grams to multi-ton lots: 1. Starting Materials for Peptide Synthesis, Peptidomimetic and Medicinal Chemistry Protected Amino Acids, Coupling Reagents, Linkers and Resins, Natural and Unusual Amino Acids and Building Blocks used in Peptide Synthesis, Peptidomimetic and Medicinal Chemistry. 2. Technologies for Drug Delivery With more than 500 different products we carry the worldwide largest portfolio of PEGylating reagents from short monodisperse to long polydispersepoly (ethylene glycol) derivatives. PASylation is a modern technology, in order to improve the pharmacokinetic properties of biopharmaceuticals produced by recombinant techniques. PGA Poly (glutamic acid) is a modern drug carrier system providing the advantages of polymer therapeutics also to small drug molecules. Multifunctional Dendrimers are sophisticated carrier tools in modern applications like Personalized Medicine and Combination Therapy. 3. Reagents for Life Sciences and Diagnostics Enzyme Substrates and Special Proteins, Diagnostic and Biochemistry Tools Natural Products, with biological and pharmacological activity, like immunsuppressiva: Aflatoxines, Cyclosporines, Geldanamycin, Rapamycin, etc.) Carbohydrates (Derivatives of Arabinose, Galactose, Glucose, Xylose, etc.) Dyes and Fluorescent labels for Peptide Synthesis and Molecular Biology 4. Biocatalysis We offer a wide range of unusual and innovative enzymes, immobilised enzymes and enzyme carriers for modern biocatalysis. The goal of our visit in Japan is to establish contact to customers working in the areas of our activities. We would like to talk to scientists and related personal of R&D and production departments in companies working in the areas peptides, medicinal chemistry, diagnostics and Life Sciences and pharmaceutical industry in general. Iris Biotech GmbH Address: Waldershofer Str , Marktredwitz, Germany Tel.: +49 (0) Fax: +49 (0) Contact: Annick Vancolen, Sales Manager E Mail: annick vancolen@iris biotech de annick.vancolen@iris-biotech.de Website:

17 NDA Regulatory Service NDA Group is a leading European regulatory and pharmacovigilance consultancy. We offer advice throughout the lifecycle of a new drug, from development and approval, to post approval activities. Our team of over 100 European-wide specialist consultants, in collaboration with our unique Regulatory and HTA Advisory Boards, are on hand to give you the best advice and support to get new drugs to the market, and keep them there. Based in Germany, Sweden and the UK, NDA supports drug companies in Europe, as well as global organisations seeking EU regulatory and pharmacovigilance advice. Our expertise spans four main areas: 1.Strategic and operational we can support clients with high level strategic advice, right through to hands-on operational requirements. 2.All substances and therapeutic areas Our experts span every part of the pharmaceutical industry and what s needed to get your drug to market, in a tailor-made fashion. This includes small molecules, biopharmaceuticals and advanced therapies 3.Unique and completely impartial advice The NDA Advisory Board gives clients top-level advice from some of Europe s leading regulatory, HTA and pharmacovigilance experts. Clients are further supported by an experienced team of over 100 project managers, subject-matter-experts, ex-regulators and advisers from across the industry. Our advice is honest, direct and delivered in a manner clients can understand. 4.National and global capability our team has the expertise to support any EU regulatory, HTA and pharmacovigilance requirement, whether you are based in Europe, the Americas, Asia or Emerging Markets. NDA Regulatory Service GmbH Address: Weihenstephaner Straße 28, Munich, Germany Tel.: +49 (0) Fax: +49 (0) Contact: Monika Eck-Schaupp, Deputy Managing Director munich@ndareg.com Website:

18 PRIAXON Priaxon is a drug discovery company that uses a unique, proprietary technology platform for the development of small molecule therapeutics. PriaXplore employs novel computational and synthetic approaches to address protein protein interactions (PPIs) in a highly innovative and efficient way. The technology has successfully been applied for the development of inhibitors of the MDM2-p53 interaction, which were partnered with Boehringer-Ingelheim on a co-development basis. With the recently founded Priaxon Inc. at the Fox Chase Cancer Center Priaxon has access to all the high class assays in oncology, which strengthens the biological competence and capacity of the company essentially. Besides several internal programs in the field of apoptosis Priaxon has developed a special business model: Priaxon works on own risk on targets coming from a partner. The success criteria concerning the developed compounds have to be mutually agreed. The partner has a right of preemption on a pre-negotiated contract basis. The exclusivity concerning the project is guaranteed. Hitting the pre-negotiated criteria triggers an outlicensing contract, which has to be mutually agreed before the start of the project. The biological screening of the compounds is carried out by the partner on the basis of a MTA. I would be glad to discuss opportunities for co-development and possible collaborations on a flexible business basis. PRIAXON AG Address: Gmunder Str a, Munich, Germany Tel.: +49 (0) Fax: +49 (0) Contact: Dr. Christoph Burdack, CSO Website:

19 SIRION BIOTECH SIRION Biotech was founded in 2006 in Munich and maintains offices in Tokyo and New Hampshire. It stands for sophisticated cell modeling and viral vector platforms. These enable much improved target identification and compound screening in the drug, the food & cosmetic industries. Its technology has over the years been validated in more than 250 commercial projects with more than 70 academic and industrial organizations worldwide. As a result, primary cell immortalizations are being technically advanced, so are the recombinant construction of adenovirus serotype vectors serving for gene therapy applications and novel vaccines. Specifically, SIRION Biotech is offering a satisfaction guarantee on gene knockdowns of nearly 100% (RNAiONE ), cell lines with built-in reporter genes (SenCELL ), next generation cell models with high on-target knockdowns. VariCHECK represents an inducible expression system for the functional analysis of protein variants. Ready-to-use-kits offer up to 50-fold transduction enhancement (AdenoBOOST ) or convenient and reliable vector cloning & purification within just 4 weeks (AdenoONE ). Commercial arrangements range from fee-for-service over exclusive rights on single clones all the way to milestone & licensing arrangements. The latter are suited for longer term complex product developments in the areas of gene therapy and vaccines. Molecular biologists experienced in the field stand ready for project discussions in Europe, Japan and USA. SIRION BIOTECH GmbH Address: Am Klopferspitz 19, Martinsried, Germany Tel.: +49 (0) Fax: +49 (0) Contact: Dr. Christian Thirion, CSO thirion@sirion-biotech.com Website:

20 SuppreMol SuppreMol, a privately held biopharmaceutical company, is developing novel proteins to treat autoimmune diseases and allergy. The company is pioneering the development of soluble Fc gamma receptors (FcγRs) and other immunomodulatory molecules and antibodies for alternative treatment strategies that have the potential to readjust the balance of the immune system. SuppreMol s lead candidate SM101 is a recombinant, soluble, non-glycosylated version of the Fc gamma receptor IIB (FcγRIIB) and has received orphan drug designation in the US and Europe for Primary Immune Thrombocytopenia (ITP). Recent Phase Ib results in ITP have shown SM101 to be safe, well tolerated and efficacious in a dose-dependent manner. Subsequent Phase IIa and IIb trials in Europe and the US will be initiated iti t in In 2011 SuppreMol started t a Phase IIa randomized, double-blind clinical trial with SM101 in patients suffering from Systemic Lupus Erythematosus (SLE). In preclinical studies SM101 has shown strong efficacy by decreasing inflammation and immune reactions. These data suggest that SM101 also has potential in Rheumatoid Arthritis (RA) and other B cell-driven autoimmune diseases. To strengthen its platform of selective immunoregulators, SuppreMol is working on antibody programs targeting Fc receptors and other immunomodulatory molecules that interfere at earlier stages of a disease. Fc gamma receptors IIB (FcγRIIB) γ are the sole inhibitory receptors on immune cells and, when co-crosslinked with activating receptors such as B cell receptor or Fc epsilon receptors, inhibit the activation of B cells or basophils/mast cells. SuppreMol s nonblocking anti-fcγriib antibodies SM201 and SM301 are utilizing that mechanism and recruit further inhibitory FcγRIIB into the cluster to effectively downregulate the exaggerated immune cell responses in autoimmune diseases and allergy. SM401, a monoclonal antibody against IL-3, has demonstrated in a murine model for Rheumatoid Arthritis (RA) that it significantly reduces progression and severity of the disease. At the same time, levels of inflammatory cytokines such as IL-6 and TNF-alpha alpha, which are reduced by several established RA drugs, are also lowered. Using a newly developed IL-3 diagnostic assay, SuppreMol expects to successfully develop a biomarker for the stratification of RA patients. SuppreMol was founded as a spin-off from the laboratory of Prof. Dr. Robert Huber, Nobel Prize in Chemistry 1988, at the Max Planck Institute for Biochemistry in Martinsried, Germany. To date SuppreMol has raised 35.8 million through private investors and 11.7 million in project funding. SuppreMol GmbH Address: Am Klopferspitz 19, Martinsried, Germany Tel.: +49 (0) Fax: +49 (0) Contact: Dr. Robert Phelps, Head of BD and Licensing E Mail: phelps@suppremol com phelps@suppremol.com Website: